10-K: Absci Corporation Reports 2024 Annual Results, Focuses on AI-Driven Drug Creation

Absci Corporation's 2024 10-K filing highlights its focus on AI-driven antibody therapeutics, partnered programs, and internal pipeline development, despite incurring a net loss of $103.1 million.

Summary

• Absci Corporation, a data-first generative AI drug creation company, released its Form 10-K for the fiscal year ended December 31, 2024.
• The company's mission is to design differentiated antibody therapeutics using its Integrated Drug Creation platform.
• Absci's platform leverages generative AI models to optimize multiple drug characteristics, aiming to shorten the time to clinic and increase the probability of success.
• The company's business model involves generating internally developed programs for partnering or out-licensing, and collaborating with third parties for early discovery efforts.
• As of December 31, 2024, Absci had four wholly-owned, internally developed programs focusing on cytokine biology.
• ABS-101 is in preclinical development as a potential treatment for Inflammatory Bowel Disease (IBD), with a regulatory filing expected in the first half of 2025.
• ABS-201 is in preclinical development as a potential treatment for androgenic alopecia (AGA), with a regulatory filing expected in the first half of 2026.
• The company reported total revenue of $4.5 million for 2024, a decrease from $5.7 million in 2023, due to the timing of project-based milestones.
• Absci incurred a net loss of $103.1 million in 2024, compared to a net loss of $110.6 million in 2023.
• Research and development expenses increased by 33% to $63.9 million in 2024, driven by the advancement of drug creation programs.
• As of December 31, 2024, Absci had $112.4 million in cash, cash equivalents, and short-term investments.
• The company expects its current resources to be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.
• Absci is actively building and expanding a portfolio of internally developed programs, each designed using its generative AI models.
• The company intends to maintain its technological differentiation through continued investment in its team and platform technologies.
• Absci is subject to extensive government regulations regarding the discovery, development, approval, and commercialization of biotherapeutics.
• The company is integrating ESG considerations into its business strategy.
• As of December 31, 2024, Absci had 157 employees.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While Absci is making progress in its AI-driven drug creation and advancing its internal pipeline, it is still operating at a loss and faces significant risks and challenges in the competitive biopharmaceutical industry. The company's reliance on partnerships and the uncertainty of regulatory approvals also contribute to a neutral outlook.

Positives

• Absci is focused on a growing market for antibody therapeutics.
• The Integrated Drug Creation platform aims to improve traditional biologic drug discovery.
• The company has a diversified business model with both partnered and internally developed programs.
• Preclinical development is underway for ABS-101 and ABS-201, with anticipated regulatory filings in the near future.
• The company has a strong cash position of $112.4 million as of December 31, 2024.
• Absci is continuously investing in its team and platform technologies.
• The company is integrating ESG considerations into its business strategy.

Negatives

• Absci incurred a net loss of $103.1 million in 2024.
• Total revenue decreased from $5.7 million in 2023 to $4.5 million in 2024.
• The company is dependent on the success of its partners in developing and commercializing product candidates.
• The biopharmaceutical platform technology market is highly competitive.
• The company relies on a limited number of suppliers for laboratory equipment and materials.
• The company's Integrated Drug Creation platform may not meet the expectations of its partners.
• The company depends on its information technology systems, and any significant disruptions could harm its business.

Risks

• The company's limited operating history makes it difficult to evaluate its business and predict future performance.
• Biologic drug development is inherently uncertain, and product candidates may not achieve development or regulatory milestones.
• Preclinical development is uncertain, and product candidates may experience delays or never advance to clinical trials.
• The company may face competition from entities with substantial investments in novel treatments.
• The market may be skeptical of the viability and benefits of the company's Integrated Drug Creation platform.
• The company relies on third parties to conduct preclinical studies and clinical trials.
• The company could experience clinical supply and manufacturing problems.
• The company may not achieve projected development goals in the timeframes announced.
• The medical insurance coverage and reimbursement status of newly approved therapeutics is uncertain.
• The company may be subject to laws that generally govern the biopharmaceutical industry.
• The company's equipment financing agreements may contain covenants that restrict its operating activities.
• The company's inability to collect on its accounts receivable by a significant number of partners may have an adverse effect on its business.
• The company's operating facility becoming damaged or inoperable may jeopardize its ability to conduct and pursue its drug creation and internal research and development efforts.
• The company's reliance on evolving technologies, such as artificial intelligence (AI), may present risks and challenges that can impact its business.
• The company's dependence on its information technology systems, and any significant disruptions to or failure of these systems could result in significant financial, legal, regulatory, business and reputational harm to its business.
• The company's international expansion of its business exposes it to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
• The company's business activities are subject to the FCPA and other anti-bribery and anti-corruption laws of the United States and other countries in which it operates, as well as U.S. and certain foreign export controls and trade sanctions.
• The company uses biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against it.
• Public health crises such as pandemics or similar outbreaks could cause a disruption of the development of its platform technologies, and adversely impact its business.
• The company relies and expects in the future to rely on a limited number of outside parties to perform the cGMP manufacturing for preclinical development, clinical development and commercialization of any biologic product candidates produced using its technology.
• The company's inability to obtain and maintain sufficient intellectual property protection for its technologies, including for its cell line and expression technologies, generative deep learning technology, proprietary assays and techniques, and antibody and target discovery technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize technologies similar or identical to ours, and its ability to successfully leverage its technologies may be impaired.
• The company may be subject to claims that its employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property.
• The company may pursue litigation, quasi-litigation, quasi-arbitral, or adversarial proceedings before trademark offices, courts, or other administrative tribunals or courts in order to enforce its trademark rights or to determine the scope, coverage and validity of its rights.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company's share price may be volatile, and you could lose all or part of your investment.
• The company in the past have had, and in the future may have, a material weakness in its internal control over its financial reporting process. If it is unable to remediate an identified material weakness, it may not be able to accurately or timely report its financial condition or results of operations.
• The company is obligated to develop and maintain proper and effective internal control over financial reporting. These internal controls may not be determined to be effective, which may adversely affect investor confidence in its company and, as a result, the value of its common stock.
• The company has historically identified, and may continue to identify, key business metrics to evaluate its business and technology, measure its performance, identify trends affecting its business, formulate financial projections and make strategic decisions, and any such metrics may not accurately reflect all aspects of its business needed to make such evaluations and decisions, in particular as its business continues to grow.
• Future sales and issuances of its common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of its stockholders and could cause its share price to fall.
• The company does not intend to pay dividends on its common stock, so any returns will be limited to the value of its common stock.
• The company's principal stockholders and management own a significant percentage of its shares and will be able to exert significant influence over matters subject to stockholder approval.
• Future sales of its common stock in the public market could cause its share price to fall.
• An active trading market for its common stock may not continue to be maintained.
• Provisions in its corporate charter documents and under Delaware law could make an acquisition of it more difficult and may prevent attempts by its stockholders to replace or remove its current management.
• Its ability to use its net operating losses and certain other tax attributes may be limited.
• Changes in tax law may adversely affect it or its investors.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about its business, its share price and trading volume could decline.
• Unfavorable U.S. or global economic conditions could adversely affect its business, financial condition or results of operations.
• Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect its current and projected business operations and its financial condition and results of operations.
• Its employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading.
• Its insurance policies are expensive and protect it only from some business risks, which leaves it exposed to significant uninsured liabilities.
• Cybersecurity incidents, data breaches, loss of data and other disruptions could compromise sensitive information related to its business or prevent it from accessing critical information and expose it to liability, which could adversely affect its business and its reputation.
• Natural and man-made disasters, including cyber-attacks and other events beyond its control could severely disrupt its operations, or those of its partners, and have a material adverse impact on its business, results of operations, financial condition and prospects.
• Social media platforms present new risks and challenges to its business.
• It is an emerging growth company, and the reduced reporting requirements applicable to emerging growth companies could make its common stock less attractive to investors.

Future Outlook

Absci expects to continue incurring significant expenses as it develops its internally developed programs, enters into additional partnerships, and invests in technology enhancements. The company believes its current resources will be sufficient to meet its needs for at least the next 12 months.

Industry Context

Absci operates in the competitive biopharmaceutical platform technology market, facing competition from companies developing AI-guided drug design, novel target identification methods, and antibody therapeutics. The company's success depends on its ability to differentiate its Integrated Drug Creation platform and demonstrate its value to partners.

Comparison to Industry Standards

• The document mentions competitors with product candidates targeting TL1A in clinical development for IBD, including Merck, Roche/Roivant, Sanofi/Teva, Spyrus, and Xencor.
• It also notes Hope Medicines' product candidate targeting PRLR in clinical development for androgenic alopecia.
• The document compares ABS-101 to clinical competitor antibodies from Merck and Roche, noting a 2-3x extended half-life in NHPs and comparable target engagement with only one-fifth of the dose.
• The document compares ABS-201 to 5% topical minoxidil in a preclinical study for short term hair growth in mice, achieving full hair growth after 22 days, whereas minoxidil only achieved approximately one-third hair growth in the same period.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in drug development will impact shareholder value.
• Employees: The company's ability to attract and retain talent is crucial for its success.
• Customers/Partners: The effectiveness of the Integrated Drug Creation platform will impact the success of partnered programs.
• Patients: The company's mission is to bring best-in-class and first-in-class antibody therapeutics to patients who need them.

Next Steps

• Continue preclinical development of ABS-101 and ABS-201.
• Pursue regulatory filings for ABS-101 and ABS-201.
• Advance internally developed programs through preclinical and clinical development.
• Seek additional partnerships to expand the scope of the Integrated Drug Creation platform.
• Continue investing in research and development to enhance the platform's capabilities.

Key Dates